
Yelena Janjigian/LinkedIn
Jul 1, 2025, 05:33
Yelena Janjigian: Amgen Reports Positive Phase 3 Results for Bemarituzumab in FGFR2b+ Gastric Cancer
Yelena Janjigian, Chief of Gastrointestinal Oncology at Memorial Sloan Kettering Cancer Center, posted on LinkedIn:
“FGFR2B expression as a bookmaker in first line GEC.
Congratulations to all the investigators.”
Read Further: Oncologist Near Me – Yelena Janjigian: A Global Leader in Gastrointestinal Oncology.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 30, 2025, 16:43